01—Abstract
Summary
Summary of the 8-K filed February 20, 2024. Cited figures are marked; the original filing is the authoritative source.
On February 20, 2024, Truist Financial Corporation (NYSE: TFC) agreed to sell its remaining equity stake in Truist Insurance Holdings (TIH), the fifth-largest U.S. insurance broker, to an investor group led by Stone Point Capital, Clayton, Dubilier & Rice, and Mubadala Investment Company.
The deal implies a $15.5 billiona enterprise value (about 18x TIH's 2023 core EBITDA) and is expected to yield roughly $10.1 billion in after-tax cash proceeds to Truist, subject to adjustments. Closing is targeted for the second quarter of 2024, pending regulatory approvals and customary conditions. From an investor standpoint, the transaction is primarily a capital event.
Management projects a 230 basis point increase in CET1 under current Basel III rules (255 bps under fully phased-in rules), a 33% (about $7.12b per share) accretion to tangible book value per share, and a roughly $0.20 dilution to 2024 EPS before any reinvestment benefits. Management intends to evaluate a balance sheet repositioning of about $23 billion of securities, with the goal of replacing TIH's earnings contribution, though this is subject to market conditions and is not guaranteed.
Key deal protections include a $700 millionc termination fee payable by the buyers in certain circumstances, an outside date of August 20, 2024 (extendable to November 20, 2024 if only regulatory conditions remain), and ancillary commercial agreements under which TIH will continue as Truist's broker of record for property and casualty coverage and as employee benefits provider. Investors should note that the filing describes the purchase agreement's representations as allocating risk rather than establishing facts, so the agreement's terms should be read with that context.
02—Key points
Key Highlights
- Sale of remaining TIH stake at an implied $15.5B enterprise value, roughly 18x 2023 core EBITDA, with about $10.1B in expected after-tax cash proceeds to Truist
- Projected CET1 uplift of approximately 230 bps under current Basel III rules and 255 bps under fully phased-in rules
- Tangible book value per share expected to rise by $7.12, or 33%, on a pro forma basis
- Estimated 2024 EPS dilution of about $0.20 before any balance sheet repositioning, which management aims to offset by replacing TIH's earnings
- Management is evaluating a potential ~$23B securities balance sheet repositioning post-closing, subject to market conditions
- $700 million termination fee payable by buyers in specified circumstances; outside date of August 20, 2024, extendable to November 20, 2024 for regulatory conditions
- Expected closing in Q2 2024, subject to regulatory approvals and customary closing conditions
03—Questions
Frequently Asked Questions
How much cash will Truist actually receive from the TIH sale?
Truist expects approximately $10.1 billion in after-tax cash proceeds. This is derived from roughly $12.6 billion in gross proceeds (including $7.6 billion for its remaining common equity and $5.0 billion for preferred stock redemption), less about $2.5 billion in taxes and transaction-related costs. The figure remains subject to adjustments for cash, debt, working capital, and transaction expenses.
Why does the sale boost capital so significantly?
The sale is expected to create about $9.5 billion of CET1 capital, comprising a roughly $4.8 billion after-tax gain and a $4.7 billion benefit from removing TIH's intangibles net of deferred tax liabilities. Risk-weighted assets are also expected to decline by about $2.2 billion. Together these drive the projected 230 bps CET1 increase.
Will Truist's earnings decline after the sale?
Management estimates the sale plus reinvestment of proceeds in cash would be about $0.20 dilutive to 2024 EPS, assuming a January 1, 2024 closing and a 4.5% cash yield. TIH contributed about $507 million of net income to Truist's parent in 2023 excluding preferred items. Management says it intends to offset this through a possible balance sheet repositioning, but that plan is not assured and depends on market conditions.
What could prevent or delay the deal from closing?
Closing depends on receiving regulatory approvals, expiration or termination of applicable waiting periods, and other customary conditions. Either party may terminate if closing has not occurred by August 20, 2024, which automatically extends to November 20, 2024 if only regulatory conditions remain unsatisfied. Truist is also subject to business conduct restrictions regarding TIH before closing.
What happens to Truist's relationship with TIH after the sale?
Upon closing, Truist and TIH will enter ancillary agreements, including a transition services agreement, a relationship marketing agreement for co-marketing and business services, a broker-of-record arrangement for Truist's property and casualty coverage, and an employee benefits provider arrangement that includes extending the LifeForce premium reduction program and flexible benefits and COBRA services.
04—Continue